BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
November 16, 2022 08:56 ET
|
BioRestorative Therapies, Inc
Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of...
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
October 20, 2022 09:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
September 28, 2022 07:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference
September 27, 2022 07:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14
September 07, 2022 07:00 ET
|
BioRestorative Therapies, Inc
BioRestorative Therapies to highlight addition of Phase 2 clinical trial for chronic lumbar disc disease to its mid-stage pipeline. Melville, NY., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative...
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 30, 2022 07:30 ET
|
BioRestorative Therapies, Inc
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22, 2022 07:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 29, 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem...
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 18, 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 04, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Certification Gives BioRestorative Therapies Clinical Grade Manufacturing Capabilities MELVILLE, N.Y., April 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...